<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811341</url>
  </required_header>
  <id_info>
    <org_study_id>2015SDU-QILU-G01</org_study_id>
    <nct_id>NCT02811341</nct_id>
  </id_info>
  <brief_title>The Application of Spasmolytic in PCLE Examination of Superior Gastrointestinal Endoscope</brief_title>
  <official_title>A Clinical Analysis of Scopolamine Hydrobromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scopolamine butylbromide might be helpful for the outcome of superior gastrointestinal
      endoscope examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The peristalsis of gastrointestinal tract has a adverse affection on the process of the PCLE
      examination .Scopolamine butylbromide is a widely used spasmolytic，which can reduce the
      peristalsis of gastrointestinal tract effectly.The application of it may benefit the
      images'quality ,the acurrate of diagnosis and shorten the examination time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endomicroscopic image quality</measure>
    <time_frame>7months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Using Copolamine Butylbromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination</condition>
  <arm_group>
    <arm_group_label>A group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Using normal saline before pcle examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using Scopolamine Hydrobromide before pcle examination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine Hydrobromide</intervention_name>
    <arm_group_label>B group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <arm_group_label>A group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  outpatients attending endomicroscopy

          -  able to give written informed consent

        Exclusion Criteria:

          -  coagulopathy

          -  acute upper digestive tract bleeding

          -  pregnancy or breast feeding

          -  allergy to fluorescein sodium

          -  impaired renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanqing Li, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital，Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yanqing Li, PhD. MD.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Gastroenterology, Qilu Hospital, Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology, Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Yanqing Li</investigator_full_name>
    <investigator_title>Vice president of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>Scopolamine butylbromide PCLE</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

